Navigation Links
Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs

SUNNYVALE, Calif., Sept. 14 /PRNewswire/ -- Molecular Devices, Inc., a long-time leader in bioanalytical systems for microplate analysis, today announced the launch of two new multi-mode detection platforms that expand its portfolio of microplate readers, enabling the company to meet all combinations of customer needs now and into the future.



Both products will be showcased at Miptec 2010, Switzerland, September 20-24, as well as several other 2010 shows including Het, Scanlab, Biotechnica, SBS China, Society for Neuroscience, and American Society for Cell Biology. Please check for details.

The SpectraMax® Paradigm® Platform is the only user-upgradeable multi-mode reader on the market today and is ideal for drug discovery research, including high-throughput screening. The FilterMax™ F3 and F5 Series Readers deliver unmatched assay performance compared to similarly priced readers and are ideal for a wide range of life science research applications. Both platforms were developed in response to requests from existing customers, and both are commercially available with shipping to begin in early October.

"With these two new platforms, we now have an ideal microplate reader for any combination of application, detection, and budget needs," said Mark Verheyden, President of Molecular Devices. "We've carefully expanded our portfolio to ensure that we will be able to meet our customers' needs across ever-evolving research environments. By adding the SpectraMax Paradigm and FilterMax™ F Series Platforms to our existing lines of readers, we now offer the most comprehensive line of microplate readers on the market today."

Read What you Want When You Want with the SpectraMax Paradigm Multi-Mode Microplate Reader

The new patent-pending SpectraMax Paradigm Platform is the only multi-mode detection platform on the market today that allows users to upgrade the functionality of their instrument directly—no service call, no factory shipment. Upgrading is as easy as selecting from over 20 mix-and-match detection cartridges and inserting them into one or more of 12 instrument slots. A single cartridge can be changed in less than 2 minutes—the instrument can be fully reconfigured in 10 to 20 minutes. This unmatched flexibility provides a platform that can easily be adapted to meet constantly evolving application needs and ever advancing detection technologies while accommodating most budgets. With multiple detection modes, including AlphaScreen and HTRF, as well as 1536-well microplate compatibility to support high-through screening, the SpectraMax Paradigm Reader is ideal for drug discovery & development, particularly for assay development, lead identification, and lead optimization.

Unmatched Assay Performance is Now Within the Reach of any Life Science Laboratory with the new FilterMax F3 & F5 Multi-Mode Readers

The new, patented FilterMax F Series Platform delivers a unique combination of value, performance, and sensitivity, putting high-performance multi-detection capabilities into the hands of any life science researcher. This unique filter-based platform delivers unmatched assay performance across a broad range of life science applications, and currently offers two models: the F3 with absorbance, fluorescence, and luminescence detection modes and the F5 with those same modes plus fluorescence polarization and time resolved fluorescence modes.

For more information, please visit, send an email to, or contact your local sales & support office.

About Molecular Devices: At Molecular Devices we have one focus—our customers. When you become our customer, your needs drive our actions and your success is our concern. Our instruments offer a full spectrum of detection technologies and meet all throughput and content needs. Our goal is to deliver highly relevant bioanalytical products to detect biology, decode data, and drive discovery.

All products are FOR RESEARCH USE ONLY. Not for Use in Diagnostic Procedures.

All trademarks are the property of Molecular Devices, Inc.

SOURCE Molecular Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
2. China Cord Blood Corporation to Launch Warrant Exchange Offer
3. DGP Group Rebrands as Intelsius and Announces Launch of New, Innovative Packaging System - Orcatherm™
4. Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU)
5. West Michigan Launches $10 Million Early Stage Venture Fund to Support Life Science & Technology
6. International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.
7. Forte Launches Probate Finder OnDemand™
8. Skin & Allergy News Digital Network Launches Product Zone
9. Transportation and Aviation Leaders Launch Sustainable Biofuels Initiative
10. FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream”
11. Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting
Post Your Comments:
(Date:11/30/2015)... 30, 2015  Champions Oncology, Inc. (CSBR), engaged in ... personalize the development and use of oncology drugs, today ... will be presenting at the LD MICRO Investor Conference ... Time (PST).  The conference, held at the Luxe Sunset ... , will feature 200 small/micro-cap companies and is ...
(Date:11/30/2015)... JACKSONVILLE, Florida , November 30, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, today announced it will be presenting ... Event on December 1, 2015 at 2.30 PM PT. ... member and Strategic Advisor will be giving the presentation ...
(Date:11/30/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare ... at two upcoming investor conferences. Aytu is scheduled to ... to be held December 3, 2015, and at LD ... 2 nd & 3 rd , 2015 in ... via webcast. Josh Disbrow , Chief Executive ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
Breaking Biology Technology:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
Breaking Biology News(10 mins):